MiMedx Group (NASDAQ:MDXG) Upgraded to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded MiMedx Group from “sell” to “hold,” while the broader analyst consensus remains “Moderate Buy” with an average price target of $8.57.
• MiMedx shares opened at $4.50, compared with a 52-week range of $3.03 to $7.97. The company’s latest quarterly results matched EPS expectations at a loss of $0.05, while revenue of $64.36 million exceeded estimates.
• Institutional ownership stands at 79.15%, with several investors adding to or initiating positions during the second quarter.

MiMedx Group (NASDAQ:MDXG - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Saturday.

Several other brokerages have also recently issued reports on MDXG. Raymond James Financial set a $8.00 price objective on shares of MiMedx Group in a research note on Monday, August 17th. Seaport Research Partners lowered shares of MiMedx Group to a "neutral" rating in a research note on Monday, August 17th. Craig Hallum raised their target price on shares of MiMedx Group from $6.00 to $8.00 and gave the stock a "buy" rating in a report on Thursday. Cantor Fitzgerald restated an "overweight" rating and issued a $8.00 price target on shares of MiMedx Group in a research report on Monday, August 17th. Finally, Weiss Ratings reaffirmed a "sell (d)" rating on shares of MiMedx Group in a report on Thursday, August 13th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $8.57.

MiMedx Group Trading Down 0.2%

Shares of MiMedx Group stock opened at $4.50 on Friday. The business has a fifty day simple moving average of $4.18 and a 200-day simple moving average of $4.09. MiMedx Group has a fifty-two week low of $3.03 and a fifty-two week high of $7.97. The firm has a market cap of $655.92 million, a price-to-earnings ratio of 112.53 and a beta of 1.45. The company has a quick ratio of 4.79, a current ratio of 5.33 and a debt-to-equity ratio of 0.07.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last released its earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.05). MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%.The firm had revenue of $64.36 million for the quarter, compared to analyst estimates of $63.46 million. On average, equities analysts forecast that MiMedx Group will post -0.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. HB Wealth Management LLC acquired a new stake in shares of MiMedx Group in the second quarter worth $51,000. Syon Capital LLC acquired a new position in MiMedx Group during the 2nd quarter valued at $45,000. Susquehanna International Group LLP raised its stake in MiMedx Group by 26.2% during the 2nd quarter. Susquehanna International Group LLP now owns 72,716 shares of the company's stock valued at $280,000 after purchasing an additional 15,101 shares during the last quarter. Two Sigma Securities LLC bought a new stake in MiMedx Group in the 2nd quarter valued at $97,000. Finally, Wellington Management Group LLP grew its position in MiMedx Group by 4.1% in the 2nd quarter. Wellington Management Group LLP now owns 349,981 shares of the company's stock worth $1,347,000 after purchasing an additional 13,883 shares during the last quarter. 79.15% of the stock is owned by institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company's core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx's product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx's principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source